MINERALYS THERAPEUTICS, INC. Increase (Decrease) in Accounts Payable and Accrued Liabilities
MINERALYS THERAPEUTICS, INC. (MLYS) reported Increase (Decrease) in Accounts Payable and Accrued Liabilities of $3.27 million for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-11.
Financial Statements › Cash Flow › Operating Activities
us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities · last filed 2026-08-11
- MINERALYS THERAPEUTICS, INC. increase (decrease) in accounts payable and accrued liabilities for the quarter ending 2026-06-30 was $3.67M, a 59.59% decline year-over-year.
- MINERALYS THERAPEUTICS, INC. increase (decrease) in accounts payable and accrued liabilities for the quarter ending 2026-03-31 was -$402.00K.
- MINERALYS THERAPEUTICS, INC. increase (decrease) in accounts payable and accrued liabilities for the quarter ending 2025-12-31 was -$8.13M.
- MINERALYS THERAPEUTICS, INC. increase (decrease) in accounts payable and accrued liabilities for the quarter ending 2025-09-30 was $1.03M, a 65.25% decline year-over-year.
- MINERALYS THERAPEUTICS, INC. increase (decrease) in accounts payable and accrued liabilities for fiscal 2025 was $427.00K, a 89.74% decline from fiscal 2024.
- MINERALYS THERAPEUTICS, INC. increase (decrease) in accounts payable and accrued liabilities for fiscal 2024 was $4.16M, a 72.38% increase from fiscal 2023.
- MINERALYS THERAPEUTICS, INC. increase (decrease) in accounts payable and accrued liabilities for fiscal 2023 was $2.42M, a 19.82% decline from fiscal 2022.
- MINERALYS THERAPEUTICS, INC. increase (decrease) in accounts payable and accrued liabilities for fiscal 2022 was $3.01M.
| Period end | Increase (Decrease) in Accounts Payable and Accrued Liabilities 3 month | Increase (Decrease) in Accounts Payable and Accrued Liabilities 6 month | Increase (Decrease) in Accounts Payable and Accrued Liabilities 9 month | Increase (Decrease) in Accounts Payable and Accrued Liabilities 12 month |
|---|---|---|---|---|
| 2026-06-30 | $3.67M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-11 | $3.27M 10-Q · filed 2026-08-11 | -$4.87M derived: sum of 3 quarters · filed 2026-08-11 | -$3.84M derived: sum of 4 quarters · filed 2026-08-11 |
| 2026-03-31 | -$402.00K 10-Q · filed 2026-05-06 | -$8.53M derived: sum of 2 quarters · filed 2026-05-06 | -$7.50M derived: sum of 3 quarters · filed 2026-05-06 | $1.57M derived: sum of 4 quarters · filed 2026-08-11 |
| 2025-12-31 | -$8.13M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-12 | -$7.10M derived: sum of 2 quarters · filed 2026-03-12 | $1.97M derived: sum of 3 quarters · filed 2026-08-11 | $427.00K 10-K · filed 2026-03-12 |
| 2025-09-30 | $1.03M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-10 | $10.10M derived: sum of 2 quarters · filed 2026-08-11 | $8.56M 10-Q · filed 2025-11-10 | -$8.12M derived: sum of 4 quarters · filed 2026-08-11 |
| 2025-06-30 | $9.07M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-11 | $7.53M 10-Q · filed 2026-08-11 | -$9.15M derived: sum of 3 quarters · filed 2026-08-11 | -$6.18M derived: sum of 4 quarters · filed 2026-08-11 |
| 2025-03-31 | -$1.55M 10-Q · filed 2026-05-06 | -$18.22M derived: sum of 2 quarters · filed 2026-05-06 | -$15.26M derived: sum of 3 quarters · filed 2026-05-06 | -$5.78M derived: sum of 4 quarters · filed 2026-05-06 |
| 2024-12-31 | -$16.67M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-12 | -$13.71M derived: sum of 2 quarters · filed 2026-03-12 | -$4.24M derived: sum of 3 quarters · filed 2026-03-12 | $4.16M 10-K · filed 2026-03-12 |
| 2024-09-30 | $2.96M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-10 | $12.44M derived: sum of 2 quarters · filed 2025-11-10 | $20.84M 10-Q · filed 2025-11-10 | $17.78M derived: sum of 4 quarters · filed 2025-11-10 |
| 2024-06-30 | $9.47M derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-12 | $17.87M 10-Q · filed 2025-08-12 | $14.81M derived: sum of 3 quarters · filed 2025-08-12 | $22.15M derived: sum of 4 quarters · filed 2025-08-12 |
| 2024-03-31 | $8.40M 10-Q · filed 2025-05-12 | $5.34M derived: sum of 2 quarters · filed 2025-05-12 | $12.68M derived: sum of 3 quarters · filed 2025-05-12 | $8.90M derived: sum of 4 quarters · filed 2025-05-12 |
| 2023-12-31 | -$3.06M derived: 10-K 12 month − 10-Q 9 month · filed 2025-02-12 | $4.28M derived: sum of 2 quarters · filed 2025-02-12 | $503.00K derived: sum of 3 quarters · filed 2025-02-12 | $2.42M 10-K · filed 2025-02-12 |
| 2023-09-30 | $7.34M derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-12 | $3.56M derived: sum of 2 quarters · filed 2024-11-12 | $5.48M 10-Q · filed 2024-11-12 | $6.32M derived: sum of 4 quarters · filed 2024-11-12 |
| 2023-06-30 | -$3.77M derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-13 | -$1.86M 10-Q · filed 2024-08-13 | -$1.01M derived: sum of 3 quarters · filed 2024-08-13 | -$745.00K derived: sum of 4 quarters · filed 2024-08-13 |
| 2023-03-31 | $1.91M 10-Q · filed 2024-05-09 | $2.76M derived: sum of 2 quarters · filed 2024-05-09 | $3.03M derived: sum of 3 quarters · filed 2024-05-09 | $4.06M derived: sum of 4 quarters · filed 2024-05-09 |
| 2022-12-31 | $846.00K derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-21 | $1.11M derived: sum of 2 quarters · filed 2024-03-21 | $2.15M derived: sum of 3 quarters · filed 2024-03-21 | $3.01M 10-K · filed 2024-03-21 |
| 2022-09-30 | $269.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-07 | $1.30M derived: sum of 2 quarters · filed 2023-11-07 | $2.17M 10-Q · filed 2023-11-07 | |
| 2022-06-30 | $1.03M derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-07 | $1.90M 10-Q · filed 2023-08-07 | ||
| 2022-03-31 | $864.00K 10-Q · filed 2023-05-15 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Viridian Therapeutics, Inc.\DE (VRDN) | United States | $2.342B | -5.38 |
| Harmony Biosciences Holdings, Inc. (HRMY) | United States | $2.399B | 11.67 |
| Vera Therapeutics, Inc. (VERA) | United States | $2.402B | -7.67 |
| uniQure N.V. (QURE) | $2.416B | -4.93 | |
| SELLAS Life Sciences Group, Inc. (SLS) | United States | $2.420B | -91.87 |
| Nurix Therapeutics, Inc. (NRIX) | United States | $2.457B | -5.39 |
| Zai Lab Ltd (ZLAB) | $2.241B | -113.34 | |
| Aurinia Pharmaceuticals Inc. (AUPH) | $2.207B | 7.18 | |
| SUPERNUS PHARMACEUTICALS, INC. (SUPN) | United States | $2.517B | -24.63 |
| Immunome Inc. (IMNM) | United States | $2.538B | -9.45 |